[go: up one dir, main page]

MX2022016375A - Combinación de conjugado de anticuerpo-fármaco e inhibidor de la cinasa relacionada con ataxia telangiectasia y rad3 (atr). - Google Patents

Combinación de conjugado de anticuerpo-fármaco e inhibidor de la cinasa relacionada con ataxia telangiectasia y rad3 (atr).

Info

Publication number
MX2022016375A
MX2022016375A MX2022016375A MX2022016375A MX2022016375A MX 2022016375 A MX2022016375 A MX 2022016375A MX 2022016375 A MX2022016375 A MX 2022016375A MX 2022016375 A MX2022016375 A MX 2022016375A MX 2022016375 A MX2022016375 A MX 2022016375A
Authority
MX
Mexico
Prior art keywords
antibody
drug conjugate
combination
atr inhibitor
drug
Prior art date
Application number
MX2022016375A
Other languages
English (en)
Inventor
Ii Jerome Thomas Mettetal
Stephen Thomas Durant
Azadeh Cheraghchi Bashi Astaneh
Alan Yin Kai Lau
Yann Wallez
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of MX2022016375A publication Critical patent/MX2022016375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un producto farmacéutico para la administración de un conjugado de anticuerpo anti-HER2-fármaco en combinación con un inhibidor de ATR. El conjugado de anticuerpo anti-HER2-fármaco es un conjugado de anticuerpo fármaco en el que un fármaco-ligador representado por la siguiente fórmula (en donde A representa la posición de conexión a un anticuerpo) está conjugado a un anticuerpo anti-HER2 a través de un enlace tioéter. También se proporciona un uso y un método terapéuticos en los que el conjugado de anticuerpo-fármaco y el inhibidor de ATR se administran en combinación a un sujeto: (ver fórmula).
MX2022016375A 2020-06-24 2021-06-23 Combinación de conjugado de anticuerpo-fármaco e inhibidor de la cinasa relacionada con ataxia telangiectasia y rad3 (atr). MX2022016375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043498P 2020-06-24 2020-06-24
PCT/IB2021/055548 WO2021260579A1 (en) 2020-06-24 2021-06-23 Combination of antibody-drug conjugate and atr inhibitor

Publications (1)

Publication Number Publication Date
MX2022016375A true MX2022016375A (es) 2023-04-04

Family

ID=76730926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016375A MX2022016375A (es) 2020-06-24 2021-06-23 Combinación de conjugado de anticuerpo-fármaco e inhibidor de la cinasa relacionada con ataxia telangiectasia y rad3 (atr).

Country Status (12)

Country Link
US (1) US20230330243A1 (es)
EP (1) EP4171650A1 (es)
JP (1) JP2023542066A (es)
KR (1) KR20230043109A (es)
CN (1) CN116635082A (es)
AU (1) AU2021298251A1 (es)
BR (1) BR112022026205A2 (es)
CA (1) CA3183867C (es)
IL (1) IL299368A (es)
MX (1) MX2022016375A (es)
TW (1) TW202216208A (es)
WO (1) WO2021260579A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121038817A (zh) * 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025083069A1 (en) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Her2-binding molecules
WO2025083071A2 (en) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Antibody-drug conjugates
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
BR112014019825B1 (pt) 2012-02-10 2021-08-24 University Of Maryland, Baltimore Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos
MX364484B (es) 2012-10-11 2019-04-29 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-fármaco.
HRP20250673T1 (hr) 2013-12-25 2025-08-01 Daiichi Sankyo Company, Limited Postupak za proizvodnju konjugata anti-trop2 antitijelo-lijek
KR102314913B1 (ko) * 2014-01-31 2021-10-19 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
KR102186027B1 (ko) 2014-04-10 2020-12-03 다이이치 산쿄 유럽 게엠베하 항her3 항체-약물 콘주게이트
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TW202532106A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
KR102816741B1 (ko) 2017-08-31 2025-06-04 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
US20210369705A1 (en) * 2018-10-15 2021-12-02 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors

Also Published As

Publication number Publication date
BR112022026205A2 (pt) 2023-03-14
TW202216208A (zh) 2022-05-01
CA3183867A1 (en) 2021-12-30
EP4171650A1 (en) 2023-05-03
CA3183867C (en) 2025-06-10
IL299368A (en) 2023-02-01
KR20230043109A (ko) 2023-03-30
CN116635082A (zh) 2023-08-22
WO2021260579A1 (en) 2021-12-30
US20230330243A1 (en) 2023-10-19
AU2021298251A1 (en) 2023-02-02
JP2023542066A (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
MX2022016375A (es) Combinación de conjugado de anticuerpo-fármaco e inhibidor de la cinasa relacionada con ataxia telangiectasia y rad3 (atr).
ZA202305073B (en) Combination of antibody-drug conjugate and parp1 selective inhibitor
MX2024008000A (es) Combinacion de conjugado de anticuerpo-farmaco e inhibidor de cinasa relacionada con ataxia telangiectasia y rad3 (atr).
JP7447183B2 (ja) 親水性抗体－薬物コンジュゲート
US20230381321A1 (en) Camptothecin conjugates
US10562977B2 (en) Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
CA3213625A1 (en) Selective drug release from internalized conjugates of biologically active compounds
BR112022014398A2 (pt) Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina
US20240131178A1 (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
MY208749A (en) Biligand drug conjugates and uses thereof
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
BR112022010360A2 (pt) Fármacos conjugados de polietilenoglicol ou um sal farmaceuticamente aceitável dos mesmos, intermediários e métodos para preparar os ditos fármacos, composição farmacêutica compreendendo os mesmos e uso terapêutico dos mesmos
CA3149263A1 (en) Targeted dendrimer conjugates
PE20231947A1 (es) Conjugados de anticuerpo y farmaco
CA3198996A1 (en) Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP2740493A1 (en) Conjugates of the B-subunit of Shiga toxin for anticancer therapies
JP5478492B2 (ja) 医薬化合物
PH12022552706A1 (en) Drug antibody conjugates
MX2025012396A (es) Conjugados que comprenden enlazadores escindibles
WO2023098691A1 (zh) 抗体药物偶联物及其用途
MX2023008341A (es) Enlazadores de ésteres de doble escisión para conjugados anticuerpo-fármaco.
MX2025004492A (es) Conjugado anticuerpo-farmaco, metodo de preparacion y uso del mismo
US20250019345A1 (en) New cannabinoid-gabapentinoid conjugates and uses thereof
PL436978A1 (pl) Zastosowanie rozpuszczalnych w wodzie kompleksów złota (III)
US20250242043A1 (en) Antibody-drug conjugate comprising antibody against human trop2 and use thereof